↓ Skip to main content

Dove Medical Press

Article Metrics

An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis

Overview of attention for article published in Drug Design, Development and Therapy, March 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
48 Mendeley
Title
An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis
Published in
Drug Design, Development and Therapy, March 2017
DOI 10.2147/dddt.s118298
Pubmed ID
Authors

LS Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore

Abstract

Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy. This is a randomized, open, active-controlled, prospective, Phase IV trial. Disease activity score (DAS28), clinical disease activity index, simplified disease activity index, erythrocyte sedimentation rate and C-reactive protein levels, global health assessment, and pain visual analog scale were evaluated at baseline visit and then every 3 months together with an assessment of side effects till 12 months. Thirty-nine RA patients were enrolled and randomized to continue disease-modifying antirheumatic drugs (DMARDs) therapy or to receive a combination of SKA low-dose cytokines formulated in concentration of 10 fg/mL orally administered at a dose of 20 drops/d for 12 consecutive months. The rate of maintenance of LDA at 12 months was superior in the group treated with low-dose cytokines compared with patients treated with DMARDs, 66.7% and 42.1%, respectively; however, the difference between the groups was not statistically significant. No side effects were reported in both groups. This is the first study using a combination of three low-dose cytokines in RA, after data published on psoriasis. These data suggest that the use of a combination of low-dose SKA cytokines may be an opportunity to explore in the management of RA.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 21%
Student > Ph. D. Student 8 17%
Researcher 5 10%
Other 4 8%
Student > Bachelor 3 6%
Other 7 15%
Unknown 11 23%
Readers by discipline Count As %
Medicine and Dentistry 11 23%
Economics, Econometrics and Finance 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Immunology and Microbiology 4 8%
Biochemistry, Genetics and Molecular Biology 3 6%
Other 5 10%
Unknown 14 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 May 2017.
All research outputs
#8,505,422
of 9,777,221 outputs
Outputs from Drug Design, Development and Therapy
#803
of 1,151 outputs
Outputs of similar age
#221,767
of 264,215 outputs
Outputs of similar age from Drug Design, Development and Therapy
#34
of 45 outputs
Altmetric has tracked 9,777,221 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,151 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,215 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.